? Leadership, Planning and Evaluation Senior Leadership of the Abramson Cancer Center (ACC) is a carefully selected group of nationally prominent individuals who have clearly defined roles, and together share overall responsibility for realizing the mission of the ACC. Senior Leaders develop and implement strategies that respond to the needs of members, fostering a creative, cohesive, and comprehensive cancer research environment that encourages transdisciplinary team science across the translational pipeline for which the ACC is well-known. Senior Leaders foster and advance basic discovery in line with strategic priorities, facilitating clinical translation. The ACC has a well-established internal, Institutional, and external Planning and Evaluation (P&E) process that engages leaders, members, and scientific and community advisors from multiple disciplines and perspectives. The goal of this process is to guide future directions, set priorities, and prioritize investments of the ACC while at the same time, providing ongoing mechanisms to monitor, assess, and adjust research progress, Programs, Shared Resources, allocations, and strategies. This cohesive process is supported by highly integrated and effective bodies, such as the Director's Advisory Council, Executive Committee, Program Leaders Committee, and committees for Shared Resources, Community Outreach and Engagement, Cancer Research Training and Education, Pilot Funds, and Clinical Informatics. External Scientific Advisory (ESAB) and Community Advisory Boards (CAB) provide critical advice and feedback. The P&E process resulted in changes in Program infrastructure; development of new Shared Resources; new leaders, resources, and tools for COE; improvements in clinical research operations; strategic recruitments; and prioritization of Developmental Funds. Complementing these efforts are Programmatic and Center-wide research seminars, meetings, and retreats that foster new interactions and collaborations with Penn colleagues and external experts. A Strategic Plan in 2016 set forth the goals for this period, and upon appointment of Dr. Vonderheide as Director, the ACC conducted a Strategic Plan Update in 2018-2019. Seven priority areas were evaluated: Experimental Therapeutics, Biomedical Informatics, Population Sciences, Immune Health, Precision Oncology, Shared Resources, and Education and Training. Priority values include relevance to the catchment area, team science, translation of discovery, risk assessment, precision profiling, leveraging of big data, behavioral research, and education and training. Rigorous internal review of Programs, Shared Resources, Developmental Funds, and the strategic plan by Senior Leaders and the ESAB ensure that the ACC continues to achieve its highest aspirations and adheres to NCI guidelines. The ACC responds to all ESAB recommendations and then reports on its actions. Taken together, integrated P&E processes successfully guided marked growth and impact of the ACC during the current funding period.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
United States
Zip Code
Huang, Mo; Wang, Jingshu; Torre, Eduardo et al. (2018) SAVER: gene expression recovery for single-cell RNA sequencing. Nat Methods 15:539-542
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32
Onorati, Angelique V; Dyczynski, Matheus; Ojha, Rani et al. (2018) Targeting autophagy in cancer. Cancer 124:3307-3318
Rebecca, Vito W; Nicastri, Michael C; Fennelly, Colin et al. (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov :
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Jang, Jeong Hoon; Manatunga, Amita K; Taylor, Andrew T et al. (2018) Overall indices for assessing agreement among multiple raters. Stat Med 37:4200-4215
Scheel, John R; Kim, Eunhee; Partridge, Savannah C et al. (2018) MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol 210:1376-1385
Romero, Sally A D; Brown, Justin C; Bauml, Joshua M et al. (2018) Barriers to physical activity: a study of academic and community cancer survivors with pain. J Cancer Surviv 12:744-752
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7

Showing the most recent 10 out of 1047 publications